Compare LUCD & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LUCD | DHF |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 160.0M |
| IPO Year | 2021 | 1998 |
| Metric | LUCD | DHF |
|---|---|---|
| Price | $0.40 | $2.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 7.8M | 531.1K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $34.40 | N/A |
| Revenue Next Year | $191.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.30 | $2.12 |
| 52 Week High | $1.63 | $2.57 |
| Indicator | LUCD | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 47.79 |
| Support Level | $0.30 | $2.16 |
| Resistance Level | $0.48 | $2.23 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 8.03 | 26.62 |
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.